Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-3102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Moderate Hepatic Impairment Group | EXPERIMENTAL | - |
| Healthy Matched Control Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MK-3102 | DRUG | Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1. |
Inclusion Criteria: Impaired Hepatic Function Participants: * A diagnosis of: 1. Chronic (\> 6 months) hepatic insufficiency 2. Stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to a...
MK-3102 is an investigational small molecule being developed for the treatment of type 2 diabetes mellitus. It is a metabolic therapeutic currently in Phase 1 clinical development. The drug is being studied in participants with impaired hepatic function to evaluate its pharmacokinetic profile.
MK-3102 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with type 2 diabetes and hepatic impairment.
MK-3102 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under study for type 2 diabetes mellitus.
MK-3102 has one completed clinical trial, NCT01767688, titled "A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)." This Phase 1 study enrolled 16 participants with type 2 diabetes and was a controlled trial involving healthy volunteers.
MK-3102 is not known to have alternative names. It is a distinct investigational compound developed by Merck & Company, Inc. for type 2 diabetes mellitus. No other names for this drug have been reported.